These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Anticancer drug discovery and development throughout the world. Schwartsmann G; Ratain MJ; Cragg GM; Wong JE; Saijo N; Parkinson DR; Fujiwara Y; Pazdur R; Newman DJ; Dagher R; Di Leone L J Clin Oncol; 2002 Sep; 20(18 Suppl):47S-59S. PubMed ID: 12235225 [TBL] [Abstract][Full Text] [Related]
24. Glyn Edwards talks about cancer drug development at Antisoma. Interview by Ulrike Knies-Bamforth and Dan Huke. Edwards G Drug Discov Today; 2005 Nov; 10(22):1491-4. PubMed ID: 16257369 [TBL] [Abstract][Full Text] [Related]
25. Differences in the interpretation of the GLP requirements by OECD monitoring authorities: the point of view from the pharmaceutical industry. Lowing RK Ann Ist Super Sanita; 2008; 44(4):395-402. PubMed ID: 19352003 [TBL] [Abstract][Full Text] [Related]
26. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice. Food and Drug Administration, HHS Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321 [TBL] [Abstract][Full Text] [Related]
27. The difficulties industry is facing with investigators. Blackledge GR Eur J Cancer; 2005 Oct; 41(15):2210-2. PubMed ID: 16214043 [TBL] [Abstract][Full Text] [Related]
28. Project data sphere to make cancer clinical trial data publicly available. Hede K J Natl Cancer Inst; 2013 Aug; 105(16):1159-60. PubMed ID: 23904505 [No Abstract] [Full Text] [Related]
29. Characteriation of clinical data packages using foreign data in new drug applications in Japan. Tanaka M; Nagata T Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162 [TBL] [Abstract][Full Text] [Related]
30. [France, an attractive country for international clinical research: 2008 survey assessed by Leem (French association of pharmaceutical companies)]. Lassale C; Sibenaler C; Béhier JM; Plétan Y; Courcier S; Therapie; 2008; 63(5):345-57. PubMed ID: 19154705 [TBL] [Abstract][Full Text] [Related]
32. Implementation of the OECD GLP principles at test facilities in Japan. Sakata S Ann Ist Super Sanita; 2008; 44(4):374-8. PubMed ID: 19351999 [TBL] [Abstract][Full Text] [Related]
33. Effect of mergers and acquisitions on drug discovery: perspective from a case study of a Japanese pharmaceutical company. Shibayama S; Tanikawa K; Fujimoto R; Kimura H Drug Discov Today; 2008 Jan; 13(1-2):86-93. PubMed ID: 18190869 [TBL] [Abstract][Full Text] [Related]
34. [What has been done for international harmonization and what remains to be solved?]. Mitsuhashi H Gan To Kagaku Ryoho; 1997 Jan; 24(2):238-45. PubMed ID: 9030237 [TBL] [Abstract][Full Text] [Related]
35. Brazil: An emerging partner in drug R&D. Rodrigues DG IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884 [TBL] [Abstract][Full Text] [Related]
36. Clinical research in Hungary. Infrastructure, organisation, legislation and framework. The situation in 2008. Blaskó G; Kardos G Therapie; 2009; 64(1):33-45. PubMed ID: 19463251 [TBL] [Abstract][Full Text] [Related]
37. [International collaborative trial: from the viewpoints of statistics and data management]. Ohashi Y Gan To Kagaku Ryoho; 2007 Feb; 34(2):312-5. PubMed ID: 17301552 [TBL] [Abstract][Full Text] [Related]
38. Sustainable solid waste management: an integrated approach for Asian countries. Shekdar AV Waste Manag; 2009 Apr; 29(4):1438-48. PubMed ID: 19081236 [TBL] [Abstract][Full Text] [Related]
39. National GLP programmes and implication of regulatory authorities for pharmaceuticals, pesticides and other chemicals. Nakashima N Ann Ist Super Sanita; 2008; 44(4):363-8. PubMed ID: 19351997 [TBL] [Abstract][Full Text] [Related]
40. [Essential conditions for the development of new anticancer drugs based on ICH-GCP]. Saijo N Gan To Kagaku Ryoho; 1998 Apr; 25(5):671-84. PubMed ID: 9571964 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]